George E Thornton

US Patent:

6676940, Jan 13, 2004

Filed:

Jul 24, 2001

Appl. No.:

09/912740

Inventors:

Dario C. Altieri - La Jolla CA
Lucia R. Languino - La Jolla CA
George B. Thornton - Ramona CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

A61K 39395

US Classification:

4241411, 4241431, 4241521, 4241561, 435 721, 5303882, 5303891

Abstract:

The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.

US Patent:

6737058, May 18, 2004

Filed:

Jul 24, 2001

Appl. No.:

09/912741

Inventors:

Dario C. Altieri - La Jolla CA
Lucia R. Languino - La Jolla CA
George B. Thornton - Ramona CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

A61K 39395

US Classification:

4241391, 4241301, 4241411, 4241521, 4241721, 5303871, 5303879, 5303881, 5303882

Abstract:

The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.

US Patent:

48821454, Nov 21, 1989

Filed:

Oct 7, 1987

Appl. No.:

7/106538

Inventors:

George B. Thornton - San Diego CA
Ann M. Moriarty - San Diego CA
David R. Milich - San Diego CA
Alan McLachlan - San Diego CA

Assignee:

Scripps Clinic and Research Foundation - La Jolla CA

International Classification:

A61K 3900
A61K 3929
C07K 700
C07K 1500

US Classification:

424 88

Abstract:

Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.

US Patent:

51437260, Sep 1, 1992

Filed:

Nov 20, 1989

Appl. No.:

7/439099

Inventors:

George B. Thornton - San Diego CA
Ann M. Moriarty - San Diego CA
David R. Milich - San Diego CA
Alan McLachlan - San Diego CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

A61K 3900
A61K 3929
C07K 700
C07K 1500

US Classification:

424 88

Abstract:

Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.

US Patent:

62655493, Jul 24, 2001

Filed:

Jul 6, 1999

Appl. No.:

9/347877

Inventors:

Dario C. Altieri - La Jolla CA
Lucia R. Languino - La Jolla CA
George B. Thornton - Ramona CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C07K 1600

US Classification:

5303879

Abstract:

The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.

US Patent:

48185272, Apr 4, 1989

Filed:

Dec 9, 1986

Appl. No.:

6/939617

Inventors:

George B. Thornton - San Diego CA
Ann M. Moriarty - San Diego CA
David R. Milich - San Diego CA
Alan McLachlan - San Diego CA

Assignee:

Scripps Clinic and Research Foundation - La Jolla CA

International Classification:

A61K 3900
A61K 3929
C07K 700
C07K 1500

US Classification:

424 88

Abstract:

Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.

US Patent:

55997902, Feb 4, 1997

Filed:

Apr 25, 1994

Appl. No.:

8/232532

Inventors:

Dario C. Altieri - La Jolla CA
Lucia R. Languino - La Jolla CA
George B. Thornton - Ramona CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

A61K 3803
A61K 3810

US Classification:

514 8

Abstract:

The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.

US Patent:

59197544, Jul 6, 1999

Filed:

Nov 12, 1996

Appl. No.:

8/748150

Inventors:

Dario C. Altieri - La Jolla CA
Lucia R. Languino - La Jolla CA
George B. Thornton - Ramona CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

A61K 3802
A61K 3817

US Classification:

514 2

Abstract:

The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.